In 1998, two children with congenital adrenal insufficiency and early-onset morbid obesity were found to have causative null mutations in POMC. In a new study, therapy with the melanocortin-4 receptor agonist setmelanotide has for the first time brought hope of a normal life to patients with POMC-deficiency.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Kühnen, P. et al. Proopiomelanocortin deficiency treated with a melanocortin-4 receptor agonist. N. Engl. J. Med. 375, 240–246 (2016).
Kievit, P. et al. Chronic treatment with a melanocortin-4 receptor agonist causes weight loss, reduces insulin resistance, and improves cardiovascular function in diet-induced obese rhesus macaques. Diabetes 62, 490–497 (2013).
Ozen, S., Ozcan, N., Ucar, S. K., Goksen, D. & Darcan, S. Unexpected clinical features in a female patient with proopiomelanocortin (POMC) deficiency. J. Pediatr. Endocrinol. Metab. 28, 691–694 (2015).
Lee, E. C. & Carpino, P. A. Melanocortin-4 receptor modulators for the treatment of obesity: a patent analysis (2008–2014). Pharm. Pat. Anal. 4, 95–107 (2015).
Kumar, K. G. et al. Analysis of the therapeutic functions of novel melanocortin receptor agonists in MC3R- and MC4R-deficient C57BL/6J mice. Peptides 30, 1892–1900 (2009).
Chen, K. Y. et al. RM-493, a melanocortin-4 receptor (MC4R) agonist, increases resting energy expenditure in obese individuals. J. Clin. Endocrinol. Metab. 100, 1639–1645 (2015).
Chen, A. S. et al. Inactivation of the mouse melanocortin-3 receptor results in increased fat mass and reduced lean body mass. Nat. Genet. 26, 97–102 (2000).
Chhabra, K. H. et al. Reprogramming the body weight set point by a reciprocal interaction of hypothalamic leptin sensitivity and Pomc expression reverts extreme obesity. Mol. Metab. http://dx.doi.org/10.1016/j.molmet.2016.07.012 (2016).
Bischof, J. M., Van Der Ploeg, L. H., Colmers, W. F. & Wevrick, R. Magel2-null mice are hyper-responsive to setmelanotide, a melanocortin 4 receptor agonist. Br. J. Pharmacol. 173, 2614–2621 (2016).
Clemmensen, C. et al. Dual melanocortin-4 receptor and GLP-1 receptor agonism amplifies metabolic benefits in diet-induced obese mice. EMBO Mol. Med. 7, 288–298 (2015).
Acknowledgements
M.J.L. is funded by NIH grants R01 DK066604, R01 DK068400 and U2C DK110768.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Low, M. New hormone treatment for obesity caused by POMC-deficiency. Nat Rev Endocrinol 12, 627–628 (2016). https://doi.org/10.1038/nrendo.2016.156
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2016.156